BioArctic Q1 Results: Strong Leqembi Sales Offset by FDA Delay and Swedish Rejection

BioArctic reported its Q1 2026 interim results, highlighting that sales of the Alzheimer’s drug Leqembi exceeded EUR 500 million during the 2025 fiscal year. This milestone triggered a EUR 20 million payment to BioArctic from its partner Eisai. However, according to reports, the U.S. FDA has extended the review period for the Leqembi subcutaneous initiation treatment sBLA by three months, while the Swedish NT Council announced it currently does not recommend the drug's introduction into the Swedish healthcare system.

The mixed results come amid a competitive landscape in the biotech sector, particularly as peers like Eli Lilly advance their own Alzheimer's therapies. Per market data, these regulatory hurdles in Europe contrast with the commercial momentum seen in other regions. The broader economic context remains stable but slow, with Eurozone GDP growing by 0.1% on a quarterly basis according to market data, which may influence government healthcare reimbursement decisions across the continent.

Moving forward, investors should monitor the conclusion of the FDA's extended review period, as the subcutaneous formulation is seen as a key catalyst for patient convenience and market penetration. While current price levels for BIOA.ST were not available in the latest database snapshot, the focus remains on global sales trajectory to offset the lack of recommendation in Sweden. Upcoming clinical data updates and further communications from Eisai regarding European distribution will be critical catalysts for the stock.